News stories about Akers Biosciences (NASDAQ:AKER) have been trending somewhat negative on Wednesday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akers Biosciences earned a news impact score of 0.00 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.8412692955792 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Akers Biosciences (NASDAQ:AKER) traded up $0.04 during midday trading on Wednesday, reaching $0.19. 58,167,199 shares of the company’s stock were exchanged, compared to its average volume of 13,056,200. The company has a market cap of $4.96, a P/E ratio of -0.32 and a beta of -0.38. Akers Biosciences has a 52-week low of $0.12 and a 52-week high of $2.90.
Akers Biosciences (NASDAQ:AKER) last posted its quarterly earnings data on Wednesday, November 15th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter. The business had revenue of $0.68 million during the quarter. Akers Biosciences had a negative net margin of 134.31% and a negative return on equity of 94.44%.
Separately, ValuEngine raised shares of Akers Biosciences from a “sell” rating to a “hold” rating in a report on Friday, December 1st.
TRADEMARK VIOLATION NOTICE: This news story was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/01/10/akers-biosciences-aker-earns-daily-coverage-optimism-rating-of-0-00.html.
Akers Biosciences Company Profile
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.